An Open-label Study to Assess the Safety and Efficacy of SYMVESS® as a Vascular Conduit in Adolescents With Extremity Arterial Injury.
← catalyst calendarNCT07762313 · readout ≤ 865 d
Sponsored by Humacyte, Inc. (industry) · HUMA — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
10estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Sep 2026 | estimated | When the study began enrolling |
| Primary completion | Dec 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Vascular Trauma
- Arterial Injury
- Arterial Bleeding
Intervention
- Biological: Acellular Tissue Engineered Vessel (Symvess)
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Treatment-Related Adverse Events
measured 12 months
Kaplan-Meier estimated patency
measured 12 months
Kaplan-Meier estimated amputation-free rate
measured 12 months
Kaplan-Meier estimated infection-free rate
measured 12 months
Permalink · HUMA's whole pipeline · Catalyst calendar · Every registered study · What changed